Seroatlas · Human Serome Atlas

SLC5A5

Sodium/iodide cotransporter

Also known as: NIS, SC5A5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q92911
Gene
SLC5A5
Ensembl
ENSG00000105641
Chromosome
19
Canonical length
643 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene encodes a member of the sodium glucose cotransporter family. The encoded protein is responsible for the uptake of iodine in tissues such as the thyroid and lactating breast tissue. The iodine taken up by the thyroid is incorporated into the metabolic regulators triiodothyronine (T3) and tetraiodothyronine (T4). Mutations in this gene are associated with thyroid dyshormonogenesis 1.[provided by RefSeq, Sep 2009]

Canonical amino-acid sequenceUniProt

643 residues, UniProt reviewed canonical sequence.

>Q92911|SLC5A5
     1  MEAVETGERP TFGAWDYGVF ALMLLVSTGI GLWVGLARGG QRSAEDFFTG GRRLAALPVG
    61  LSLSASFMSA VQVLGVPSEA YRYGLKFLWM CLGQLLNSVL TALLFMPVFY RLGLTSTYEY
   121  LEMRFSRAVR LCGTLQYIVA TMLYTGIVIY APALILNQVT GLDIWASLLS TGIICTFYTA
   181  VGGMKAVVWT DVFQVVVMLS GFWVVLARGV MLVGGPRQVL TLAQNHSRIN LMDFNPDPRS
   241  RYTFWTFVVG GTLVWLSMYG VNQAQVQRYV ACRTEKQAKL ALLINQVGLF LIVSSAACCG
   301  IVMFVFYTDC DPLLLGRISA PDQYMPLLVL DIFEDLPGVP GLFLACAYSG TLSTASTSIN
   361  AMAAVTVEDL IKPRLRSLAP RKLVIISKGL SLIYGSACLT VAALSSLLGG GVLQGSFTVM
   421  GVISGPLLGA FILGMFLPAC NTPGVLAGLG AGLALSLWVA LGATLYPPSE QTMRVLPSSA
   481  ARCVALSVNA SGLLDPALLP ANDSSRAPSS GMDASRPALA DSFYAISYLY YGALGTLTTV
   541  LCGALISCLT GPTKRSTLAP GLLWWDLARQ TASVAPKEEV AILDDNLVKG PEELPTGNKK
   601  PPGFLPTNED RLFFLGQKEL EGAGSWTPCV GHDGGRDQQE TNL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC5A5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
13
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
134 nTPM

Expression across tissuesHPA

Tissue

  • choroid plexus: 134 nTPM
  • salivary gland: 61 nTPM
  • stomach: 56 nTPM
  • thyroid gland: 11 nTPM
  • cervix: 5.2 nTPM
  • cerebellum: 2.1 nTPM

Single-cell type

  • foveolar cells: 852 nCPM
  • conjunctival goblet cells: 552 nCPM
  • choroid plexus epithelial cells: 419 nCPM
  • retinal pigment epithelial cells: 68 nCPM
  • salivary duct cells: 49 nCPM
  • breast lactating cells: 31 nCPM

Immune cell

  • naive CD4 T-cell: 1.2 nTPM
  • basophil: 1 nTPM
  • memory CD4 T-cell: 0.9 nTPM
  • naive CD8 T-cell: 0.9 nTPM
  • neutrophil: 0.6 nTPM
  • T-reg: 0.6 nTPM

Brain region

  • choroid plexus: 352 nTPM
  • hippocampal formation: 23 nTPM
  • cerebellum: 13 nTPM
  • thalamus: 8.4 nTPM
  • cerebral cortex: 4.1 nTPM
  • midbrain: 2.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC5A5.

Disease | AllUniProt

Conditions SLC5A5 is implicated in, by any mechanism.

Disease | GeneticClinVar

51 pathogenic / likely-pathogenic of 569 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.56
gnomAD pLI
0
gnomAD missense Z
0.92
DepMap mean gene effect
-0.23
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC5A5 as an antibody target. Whether an autoantibody or antibody against SLC5A5 could matter depends on whether native SLC5A5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC5A5 is annotated at the cell surface, where native SLC5A5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC5A5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC5A5. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...